NCT02209155

R-Verapamil for the Prophylaxis of Episodic Cluster Headache

A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of R-Verapamil in the Prophylaxis of Episodic Cluster Headache

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Center Laboratories, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This is a double-blinded, randomized, parallel, placebo-controlled phase 2 study to evaluate the safety and efficacy of R-verapamil in the prophylaxis of episodic cluster headache.

Detailed description

Approximately 30 subjects (about 15 per treatment group),will be enrolled and randomized to receive either R-verapamil or placebo for 2 weeks. The study will consist of a 1-week run-in period and a 2-week treatment period (R-verapamil or placebo). The total duration of the study for each treatment group is 3 weeks.

Conditions

• Episodic Cluster Headache

Interventions

Type	Name	Description
DRUG	R-verapamil 75 mg tablet
DRUG	Placebo

Timeline

• Start date: 2013-11-01
• Primary completion: 2018-03-01
• Completion: 2018-03-01
• First posted: 2014-08-05
• Last updated: 2018-04-11

Locations

1 site across 1 country: United Kingdom